Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isotretinoin + interferon alfa-2b + docetaxel + estramustine
- Development stage
- Phase 2
- Lead developer
- University of Medicine and Dentistry of New Jersey
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular
01
Overview
R.I.T.E. is a combination chemo-immunotherapy regimen consisting of isotretinoin (13-cis retinoic acid), recombinant interferon alfa-2b, docetaxel (Taxotere), and estramustine phosphate sodium. Developed and studied by the University of Medicine and Dentistry of New Jersey (UMDNJ), this regimen was designed to treat hormone-refractory metastatic prostate cancer. The combination leverages multiple mechanisms: docetaxel stabilizes microtubules to inhibit cell division, estramustine disrupts microtubules and provides estrogenic effects, interferon alfa-2b acts as an immunomodulator and anti-proliferative agent, and isotretinoin promotes cell differentiation. By combining these diverse modalities, the R.I.T.E. regimen aims to overcome drug resistance and enhance tumor cell death in advanced prostate cancer patients.
- Other names
- RITE regimenRITE trial regimen13-cis retinoic acid + alpha interferon + docetaxel + estramustine
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)APC (Activated protein C)RAR (Retinoic acid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on isotretinoin + interferon alfa-2b + docetaxel + estramustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isotretinoin + interferon alfa-2b + docetaxel + estramustine.